Novartis Vaccines Portfolio Gets A Boost With Access To Intercell Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Intercell’s antigen-based research approach will complement Novartis’ protein-based work, Novartis tells “The Pink Sheet” DAILY.